Sitemap

Sitemap

Pages

Posts

Sections

Blog

Education

Events

Guidelines

Videos

Award Gallery

Vacancies

Publications

Peri-operative Chemotherapy in Muscle Invasive Bladder Cancer: Overview and the unmet clinical need for an alternative adjuvant therapy as studied in the MAGNOLIA clinical trial.
Hospital acquired urinary tract infections in urology departments: Pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies.
Evolution: A European registry evaluating management practices of pharmacologically treated patients with LUTS associated with BPH. Symptomatic improvement, progression and treatment discontinuation results. A comparison between European countries.
European registry evaluating management practices of general practitioners and urologists and pharmacological treatment outcomes in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
European registry evaluating management practices of general practitioners and urologists and pharmacological treatment outcomes in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
A randomized, double blind, placebo controlled phase II trial to evaluate the safety and efficacy of recMAGE-A3 + AS15 antigen specific cancer immunotherapy in patients with MAGE-A3 positive muscle invasive bladder cancer after cystectomy
Zoledronic acid for the prevention of bone metastases in high risk prostate cancer patients.
Zoledronic acid for the prevention of bone metastases in high risk prostate cancer.
Effectiveness of Zoledronic acid for the prevention of bone metastases in high-risk prostate cancer patients.
Effectiveness of zoledronic acid for the prevention of bone metastases in high risk prostate cancer patients.
Effectiveness of zoledronic acid for the prevention of bone metastases in high-risk prostate cancer patients.
EAU CRO and EU / USA regulations, international standards and industry best practices”.
Use of neoadjuvant chemotherapy for muscle invasive bladder cancer is low among major European centres: results of a feasibility questionnaire
Effectiveness of zoledronic acid for the prevention of bone metastases in high risk prostate cancer patients.
Important features of nosocomial urinary tract infections in urology departments. Data from PEP and PEAP studies.
ZEUS, the quest for the Holy Grail of prostate cancer bone metastases prevention continues.
Can zoledronic acid prevent bone metastases in high-risk non-metastatic prostate cancer patients ? Efficacy and safety results of the Zometa European Study (ZEUS).
Healthcare-associated urinary tract infections in hospitalized urological patients–a global perspective: results from the GPIU studies 2003-2010.
Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study.
Prostate Biopsies Should Be Performed According to a Standard of Care.
Infective complications after prostate biopsy: Outcome of the Global Prevalence of Infections in Urology (GPIU) prostate biopsy study 2010 and 2011 – a prospective, multinational, multicentre prostate biopsy study.
Antibiotic prophylaxis in urology departments 2005-2010.
Периоперационная химиотерапия при инвазивном раке мочевого пузыря: современные представления и обоснование необходимости поиска альтернативных методов лечения.
Therapies used in prostate cancer patients by European urologists: data on indication, with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates.
Prevalence of Hospital-Acquired Urinary Tract Infections in Urology departments.
A new player enters the field of European basic and clinical urological research.

Releases

×